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NC-ND license (http://creativecommoSummary Purpose: Preliminary testing of a new biodegradable inferior vena cava filter in a
canine model.
Methods: The biodegradable filter consisted of two parts, a filter cone and a stent. The filter
cone was constructed of six polyglycolic acid polymer strands anchored to a handmade absorb-
able stent. Central inferior vena cava fixation was accomplished by the absorbable stent,
which was made of polycaprolactone. Device insertion was performed through a 9F sheath un-
der ultrasound guidance on 10 adult beagles. The filters were operatively retrieved at 6 weeks
after implantation. The inferior venae cavae were subsequently analyzed grossly and using
light microscopy.
Results: None of the 10 beagles had abnormal vital signs. All of the 10 filters migrated cephalad
approximately <2 cm and remained below the renal vein ostia. One specimen had evidence of
incorporated residual strands within the caval wall on gross examination. The caval wall became
thickened at the level of filter placement without significant lumen narrowing. There was no ev-
idence of pulmonary embolism caused by degradation products of the absorbable strands.
Conclusion: Biodegradable inferior vena cava filters are feasible and potentially could be used in
specific patients who are at temporary high risk of venous thromboembolism.
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4.0/).ng authors declare no conflicts of interest.
ersity 9th School of Clinical Medicine & Capital Medical University Affiliated Beijing Shijitan Hospital,
g 10038, PR China.
om (H. Li).
15.05.002
rgical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
Figure 1 Schematic drawing of the biodegradable vena cava
filter deployed in the vena cava. It consists of two parts, a filter
cone and a stent. The filter cone is constructed of six poly-
glycolic acid polymer strands anchored to an absorbable stent.
The absorbable stent, made of polycaprolactone, attaches the
filter to the vena cava after deployment.
Figure 2 Our handmade biodegradable vena cava filter for
implantation in canine vena cava.
New biodegradable vena cava filter 131. Introduction
Pulmonary embolism (PE) is a common and potentially le-
thal disease that causes approximately 200,000 deaths/y in
the USA.1 For almost one-quarter of PE patients, the initial
clinical presentation is sudden death.2 The vena cava filter
(VCF) is designed to prevent fatal PE by capturing any large
emboli from the legs and pelvis. VCF placement has
increased significantly since the Greenfield filter was
introduced in 1973. The number of patients who have
received VCF in the USA for the prevention of PE has
increased from 2000 in 1979 to 49,000 in 1999, and there
has been a threefold increase from 2001 to 2006.3,4 The
primary reason for this increase is the introduction of
retrievable filters, which has expanded prophylactic use.
Despite the large number of VCFs used worldwide, there
has been only one randomized trial on permanent filters. The
PREPIC trial demonstrated the initial beneficial effect of
vena caval filters for the prevention of PE was counter-
balanced by an excess of recurrent deep-vein thrombosis
(20.8% vs. 11.6%), without any difference inmortality.5 After
8 years of follow up, the PREPIC trial data confirmed the
early findings of reduced risk of PE but increased incidence of
recurrent deep-vein thrombosis (35.7% vs. 27.5%).6
Retrievable VCFs theoretically can overcome the long-
term complications associated with permanent filters; they
offer protection against PE during the period of highest risk
with the option of removal before becoming permanently
incorporated into the vena cava. However, rates of attemp-
ted retrieval are low, primarily due to loss to follow up.
Karmy-Jones et al7 reported that only 22% of optional VCFs
placed in 446 trauma patients were retrieved. A similar
dismal removal rate of only 21% in>5000 patients studiedwas
reported by Antevil et al.8 Removal is invasive and may cause
additional complications that increase hospital stay and cost.
The biodegradable VCF is an innovative concept. The
biodegradable endovascular stent is a promising device that
may replace traditional metallic stents for endovascular
treatment. A recent study has demonstrated the efficacy,
biocompatibility, and safety of fully biodegradable stents in
human coronary arteries after >10 years’ follow up.9
Biodegradable polymers including poly-l-lactic acid, poly-
glycolic acid, poly(D,L-lactide/glycolide) copolymer, and
polycaprolactone (PCL), as well as magnesium alloy, have
been widely used to construct absorbable stents.10,11
Enlightened by the biodegradable stent, we developed a
new vena cava filter made totally of biodegradable mate-
rial. It would provide the critical protection against PE at
the period of the highest risk, while eliminating the long-
term disadvantages of a permanent filter and avoiding the
risks of a secondary procedure retrieving the filter.
The purpose of this study was to evaluate the feasibility,
safety, and complications of a new biodegradable filter in a
canine model.
2. Materials and methods
2.1. Filter design
The biodegradable filter consisted of two parts, a filter
cone and a stent (Figure 1). The filter cone was constructedof six polyglycolic acid polymer strands anchored to a
handmade absorbable stent. The conical filter design made
it possible to collect large thrombi while maintaining the
maximum cross-sectional area for blood flow. The absorb-
able stent, which was made of PCL, anchored the filter to
the vena cava after deployment. The diameter of the PCL
strand we used was 1.0 mm. The PCL strand was bent
consecutively by forceps to form 12 1.5-cm long struts of a
Z-stent. Two Z frameworks were connected vertically using
4-0 Monocryl suture (Ethicon Inc., Somerville, NJ, USA) to
construct a stent. The length of the stent was 2.5 cm, and
diameter was 18 mm on full expansion. Six polyglycolic acid
strands (Vicryl 3-0; Ethicon Inc.) were attached to the stent
using six knots at each fixation point (Figure 2). The height
Figure 3 (A) Inferior vena cava specimen opened with black
arrow depicting direction of blood flow. The biodegradable
stent was embedded into the caval wall. There was an intense
inflammatory response with significantly thickened vessel wall.
(B) Hematoxylin and eosin staining of the inferior vena cava
specimen. Tunica intima and media became thickened
compared with normal venous wall. The boundary between
intima and media was not clear. Smooth muscle cell hyper-
plasia with inflammatory cell infiltration occurred in tunica
media (magnification 40).
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a 9F sheath with the apex of the cone in a cephalad di-
rection and not extending beyond the renal veins.
2.2. In-vivo study
Our research protocol was approved by the Peking Univer-
sity Animal Care and Use Committee. The in-vivo study was
performed in 10 adult beagles weighing 12e15 kg each. The
average diameter of the beagle’s inferior vena cava was
12 mm based on ultrasound. A handmade and gas sterilized
biodegradable filter was inserted into the inferior vena cava
(IVC) of each beagle.
General anesthesia was administered before the proce-
dure by a veterinary technician. Anesthetic depth was
monitored by checking heart rate, respiratory rate and
depth, color of mucous membranes, capillary refill time,
and palpebral reflex every 10e15 minutes. The right com-
mon femoral vein was approached through a longitudinal
incision in the groin. After adequate dissection of the
vessel, a 10-mm longitudinal venotomy was performed on
the anterior surface of the right common femoral vein. A 9F
sheath was carefully inserted along the guidewire through
the venotomy site. The filter was implanted in the
infrarenal vena cava approximately 2 cm below the renal
vein ostia under ultrasound guidance. Venotomy was
repaired using 5-0 polypropylene (Prolene; Ethicon Inc.)
suture in a running fashion. The incision was closed in three
layers.
The operative site was dressed for the first 7 days after
the procedure and observed closely for infection. Antibi-
otics were administered orally the first 3 days. Vital signs
including heart rate, respiratory rate, body temperature,
activity, and feeding were recorded daily. Any dogs with
wound infections or abnormal vital signs were evaluated by
a veterinarian and appropriately treated. The filters were
operatively retrieved at 6 weeks after implantation. The
retroperitoneum and pericaval tissues were examined for
obvious signs of inflammation, thrombosis, or vena cava
perforation. Approximately 4 cm of the inferior vena cava
above and below the filter was removed. After removal of
the specimen, the dogs were euthanized by intravenous
injection of 30 mL of 10% potassium chloride to reduce the
chances of postmortem thrombosis affecting the inferior
vena cava. The lungs were also removed to observe any PE
caused by the degradation products of the biodegradable
filter. The IVC was observed by naked eye for degree of
degradation of the absorbable material or thrombus and
then stored in formalin. The specimens were sent to a
single pathologist for hematoxylin and eosin (HE) staining.
The same pathologist examined all the specimens for signs
of inflammation in the IVC wall and PE in the lungs; any
other changes that could be associated with the filter were
also evaluated.
3. Results
During the 6-week study period, all 10 beagles survived and
remained healthy, active, and without postoperative
wound infection. At autopsy, we found that all the filters
migrated cephalad. The migration distance was <2 cm andthe filter remained below the renal vein ostia. In nine of the
10 filters, the absorbable strands had completely dissolved
at the time of operative removal. On gross examination,
one specimen had evidence of incorporated residual
strands within the caval wall. New intima was formed at the
site where the strands embedded into the caval wall,
resulting in 80% of luminal obstruction. All of the biode-
gradable stents did not change on gross examination and
were embedded into the caval wall. The caval wall was
thickened at the level of filter placement without signifi-
cant lumen narrowing.
On HE staining, all the specimens showed an intense
inflammatory response with significantly thickened intima
and media (Figure 3). The HE slides showed inflammatory
cell infiltration and large foreign body granulomas forma-
tion in the vena cava wall. There was significant foreign
body material within each of the granulomas, which was
theorized to be the resorbed absorbable strands. There was
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absorbable strands.4. Discussion
We designed the biodegradable filter with the aim of
avoiding limitations of the current available filters. The
novel vena cava filter is made entirely of biodegradable
polymers. It provides temporary protection against fatal
pulmonary embolism during the period of highest clinical
risk. Because it is degradable, a second operation to
remove the filter is not necessary. Thus it avoids the
disadvantage of the current retrievable filter. However, the
biodegradable filter cannot be used as a permanent filter if
it is really needed for life-long prevention of PE. Therefore,
it is ideal for major trauma patients and elective surgery
patients who are at high risk for venous thromboembolism
temporarily.
During our design of the biodegradable vena cava filter,
the timing of degradation of the device was carefully
considered. A cohort study of 971 trauma patients demon-
strated the median time of fatal PE after major trauma was
18 days.12 Another study of 1067 trauma patients in the
intensive care unit indicated themean delay of development
of PE was 11.3  9.3 days.13 The risk of venous thrombo-
embolism after surgery is highest during the first 2 weeks
after surgery.14 The filter cone (made of polyglycolic acid
polymer strands) is designed to be completely absorbed in 6
weeks, and the degradation time of the stent (made of PCL)
is >24 months.15 Hence, the filter can provide critical pro-
tection against PE during the period of highest risk. The filter
cone will not migrate during the degradation because the
degradation time of the stent is longer. PCL is a biodegrad-
able synthetic polyester with a low melting point of
approximately 60C. It can be degraded into CO2 and H2O;
the degradation rate is dependent on its molecular weight
and degree of crystallinity.16 PCL has been approved by the
American Food and Drug Administration in specific applica-
tions such as surgical suture and drug delivery. We can also
use copolymer to control the degradation time according to
the individual period of risk.
An important concern of the biodegradable filter is that
if a significant thrombus is captured, it may potentially
migrate and cause PE as the filter is dissolved. Another
retrievable filter should be inserted at the time when a
significant clot is identified.
Another concern is what effects can the filter materials
have during the degradation if they migrate to the lungs. In
this study, we found no evidence of PE or pulmonary artery
inflammation. However, as these are results of short-term
follow up, the biodegradable stent is still in the vena cava.
Further studies are needed to address these problems.
Migration of the filter is a well-recognized and poten-
tially life-threatening complication. Because the device
was handmade, there was no anchoring hook, and the
radial force of the biodegradable stent was not strong
enough to ensure close attachment to the vena cava wall.
These two limitations caused migration, which can be
overcome by increasing the radial force of the stent and
adding anchoring hooks through a computerized
manufacturing process.Obvious inflammatory response of the inferior vena cava
wall was seen during this study, which is consistent with the
research carried out by Thors and Muck.17 The biodegrad-
able polymer can be coated with heparin or thrombolytic
agents, which could theoretically reduce the inflammatory
response and risk of thrombosis.
This study had several limitations. Assessment of clinical
efficacy using thrombus models was not performed during
this study; the precise degradation time of the materials
within the bloodstream is still unknown, which will be a
primary area of focus in subsequent studies. Further
modification of the filter needs to be made to solve the
migration issue. The dynamic change of the filter after
placement must be monitored in future research.
In conclusion, this study demonstrated the feasibility of
a new vena cava filter made totally of biodegradable ma-
terials. This filter can be used in specific patient pop-
ulations at temporary high risk of venous
thromboembolism. Further studies are necessary to prove
its efficiency and the anchoring mechanism should be
improved to ensure its safety.
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